March 13, 2015

A new report by the National Governors Association (NGA) is symbolic of the growing recognition of pharmacy’s vital role in healthcare delivery.

March 13, 2015

As the editor of Drug Store News, I am frequently reminded that the stories we report on extend far beyond the industry we cover.

March 13, 2015

Pharmacies and clinics on wheels? That’s the premise behind the growing effort by retail pharmacy and clinic providers to expand their reach via specially equipped buses and other vehicles that provide on-the-spot, temporary access to needed health services in hundreds of communities nationwide.

March 13, 2015

Six years. That’s how long it usually takes for any candidate to earn the Doctor of Pharmacy degree, or PharmD, now required to practice as a licensed pharmacist. In addition, PharmD graduates also must pass state licensure examinations required by state boards of pharmacy in all 50 states.

March 13, 2015

“Drugs don’t work in patients who don’t take them.”

March 13, 2015

Thank you to the 114th Congress for welcoming the participants in the 2015 NACDS RxIMPACT Day on Capitol Hill! We appreciate the opportunity to meet with you and discuss the key policy issues that shape pharmacy patient care for your constituents.

March 12, 2015

Drug Channels Institute on Thursday listed the leading specialty pharmacy players. 

March 11, 2015

Mylan launched its fentanyl transdermal system in 37.5-, 62.5- and 87.50-mcg/hr dosage strengths in the United States.

March 11, 2015

Mylan on Wednesday announced the launch of disulfiram tablets USP in dosage strengths of 250 mg and 500 mg.

March 10, 2015

ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths.

March 10, 2015

The Food and Drug Administration recently published bio-equivalence guidance documents. 

March 9, 2015

DSN examines chain pharmacy, including in-depth coverage of provider status, kiosks, Medicare and the GPhA elections, in this multi-page report.

March 6, 2015

The Food and Drug Administration approved Zarxio, making it the first approved biosimilar product in the United States.

March 5, 2015

CHPA announced its strong support for the Restoring Access to Medicines Act of 2015 (H.R. 1270).

March 5, 2015

Nutramax Labs announced Thursday the results of a National Institutes of Health-funded clinical study carried out at the Fred Hutchinson Cancer Research Center in Seattle.

 

March 5, 2015

Rite Aid sees increase in year-to-date comps as total sales increase 3.7%.

March 4, 2015

Almost half of all circular ads in support of a digestive remedy promote an antacid tablet. 

March 4, 2015

In preparation for the Consumer Healthcare Products Association’s 2015 Annual Executive Conference being held in Bonita Springs, Fla., this month, Drug Store News sat down with both Scott Melville, CHPA president and CEO, and Patrick Lockwood-Taylor, CHPA chair and VP personal health care, North America, for Procter & Gamble.

March 4, 2015

Drug Store News has partnered with Competitive Promotion Report and IRI to create a series of exclusive reports. This edition explores cold/allergy/sinus products in both the liquid/powder and tablets/packets segments.

March 4, 2015

While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.

March 4, 2015

Pharmacy Quality Alliance and AllazoHealth announced the formation of a formal research partnership to study and improve medication adherence metrics.

 

March 2, 2015

The FDA is expected to issue new guidance on biosimilars labeling and generic opioids before the end of year, according to a report by the Regulatory Affairs Professional Society.

February 26, 2015

Congress introdues legislation to protect FDA user fees from sequestration. 

February 26, 2015

The fixed-combination drug Avycaz was granted priority review by the Food and Drug Administration.